Long-Acting Cabotegravir and Rilpivirine: Innovation, New Challenges, and Opportunities
Clin Infect Dis
.
2023 May 3;76(9):1655-1657.
doi: 10.1093/cid/ciad024.
Authors
Josep M Llibre
1
,
Daniel A R Kuritzkes
2
Affiliations
1
Division of Infectious Diseases, University Hospital Germans Trias, and Fight Infections Foundation, Badalona, Barcelona, Spain.
2
Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
PMID:
36660823
DOI:
10.1093/cid/ciad024
No abstract available
Publication types
Editorial
Comment
MeSH terms
Adult
HIV Infections* / drug therapy
HIV Infections* / virology
HIV-1*
Humans
Pyridones
Rilpivirine / therapeutic use
Substances
Rilpivirine
cabotegravir
Pyridones